Evidence map›Paper›PMID 29363179›Full record

ArticleImmunology and cell biology2018

HLA-DR

Sofya A Erokhina, Maria A Streltsova, Leonid M Kanevskiy, William G Telford, Alexander M Sapozhnikov, Elena I Kovalenko

Open access · greenAbstract read
In one paragraph

Article in Immunology and cell biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 74 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. The causal effect of natural killer cells on COVID-19 infection, hospitalization and severity.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Article
  12. Article
  13. Article
  14. NK cells in HPV-related tumorigenesis: mechanisms and clinical applications.Frontiers in cellular and infection microbiology · 2025
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Sofya A ErokhinaLaboratory of Cell Interactions, Department of Immunology, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Science, Moscow, Russia.
Maria A StreltsovaLaboratory of Cell Interactions, Department of Immunology, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Science, Moscow, Russia.
Leonid M KanevskiyLaboratory of Cell Interactions, Department of Immunology, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Science, Moscow, Russia.
William G TelfordExperimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Alexander M SapozhnikovLaboratory of Cell Interactions, Department of Immunology, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Science, Moscow, Russia.
Elena I KovalenkoLaboratory of Cell Interactions, Department of Immunology, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Science, Moscow, Russia.
Institute of Bioorganic Chemistry · RUNational Institutes of Health · US

Funding

FACS Core FacilityZICBC011138 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI TELFORD, WILLIAM · 2009 to 2025
$14.5M
Intramural NIH HHS ZIC BC011138
6 · The paper itself

Abstract

NK cells change their phenotype and functional characteristics during activation. In this work, we searched for a relationship of HLA-DR expression with differentiation stages and functional activity of NK cells ex vivo and stimulated in vitro with IL-2 challenged with gene modified feeder K562 cells expressing membrane-bound IL-21 (K562-mbIL21). This stimulation technique has been described for NK cell expansion in clinical use. We have observed that HLA-DR expression in freshly isolated circulating NK cells was mostly associated with less differentiated CD56

Indexed as

BiomarkersCell DeathCell DifferentiationCell ProliferationCell SeparationCytotoxicity, ImmunologicHLA-DR AntigensHumansInterferon-gammaInterleukin-2K562 CellsKiller Cells, NaturalPhenotypeBiomarkersHLA-DR AntigensInterferon-gammaInterleukin-2HLA-DRHuman NK cellsIL-2IL-21NK cell activation

Identifiers

PMID29363179
PMCPMC8063572
OpenAlexW2783997313

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.